Synthes Case

I think that once there is a successful procedure done there will initially be a very small market for human

Ecton is going to position the company to be acquired but the board of directors and clinical advisors has some concerns about the ramifications of that plan. This paper evaluates Cannon’s Phase III Plan on March 1998. Cannon proposed a path for the next year containing five major points (Edward, 1999, 8 and 9). The bottom line of this proposal is positioning Ecton to be acquired by the end of the 1998. One of the crucial concerns of this acquisition is the possible effects on “Ecton’s product development process”. Another concern Cannon holds is the ability of Ecton to penetrate a very harsh market fills with big, established, and advanced manufacturers. Also, Cannon is not sure on how to approach specific market

This is a case about Eric Peterson, who was recently hired as a product manager in charge of sales and marketing of Biometra’s catheter. This product from Biometra, a subsidiary of Scientific Materials (SciMat), was the first product ever launched by Biometra and so its success was critical for both Biometra and SciMat. From the case we see that even though Eric Peterson tries hard to meet the product target launch date, there are several issues that he and the organization are experiencing.

Supporting detail 1: With the advent of organ transplantation more than thirty years ago, the human body has quickly created a demand for replacement parts.

Comparing these potential market size, we can easily observe that Oxyglobin is roughly two times as profitable as Hemopure. Accordingly, Biopure should take these data into account to evaluate whether or not to launch Oxyglobin immediately. On the other hand, this revenue expectation is not so realistic. In fact, it is almost impossible that the company will capture the whole potential markets because of its small production capacity. This latter represents the main obstacle to a potential success of Biopure in both animal and human

Throughout the article, “The Role of Federation Programs in the Transfer of Biomedical Technology” the Associate Director National Library of Medicine presents the valid and relevant discussion on the role federal programs input into the transfer of biomedical technology by going in-depth on the link between the government and economic funding for the research of artificial organs as the pathway for future medical technology. Phillips mentions in the key concepts in presentation to support his argument that federal programs are critical for the advancements and sources possible for conducting more reliable research on artificial organs, by suggesting that the prime contributor to the opportunities posted in disseminating cutting edge research has been the American Society for Internal Organs (ASAIO). Moreover, he makes the note that federal programs have enabled the growth of (ASAIO). The author also issues the claim that in the 21st century there has been a large-scale emergence of the molecular century as was adhered by President Bush who signed the 21st Century Nanotech Research and Development Act in 2004 that committed $3.7 billion to nanotechnology research. Additionally, cost effectiveness in comparison to conventional therapy, demonstrates a higher viability of artificial organs in the long run is

NME’s provide a higher return, but rarely make it to market compared to LCM products. The displacement of excess funds can either be invested into further research or be distributed to employees annually. If reinvested, additional capital could be used to further fund NME’s, or to market LCM’s. Evaluating individual projects and devoting special attention to their expected profitability or fit could produce alternatives as well. General Practitioner (GP), Niche, and Specialized products also offer additional lines of alternative products for evaluation and consideration.

With the latest medical advances in processing, preserving and storing, organs and tissues can be maintained for a much longer period. In addition to this, work on xenotransplantation ( animal to human transplantation) and stem cell research shows promising results in the near future. Regardless of all this, the gap between demand and supply is continuously widening with a patient being added to the waiting list every ten

Organ donation provided a new therapeutic path when new drugs and devices failed to reduce the mortality and morbidity rate of patients with such illnesses as cardiovascular diseases. By replacing damaged organs or tissue with a functioning substitute, organ transplantation offers an immediate cure. Unfortunately, this “cure” is never guaranteed because of the high risk of graft rejection and that’s if a suitable donor can be found. Thus, tissue engineering has been the projected new treatment for these problems. Tissue engineering replaces the diseased or damaged tissue or organs with biofabricated counterparts made using the specifications dictated by the features of the specific tissue or organ.

The two essays that I choose for the synthesis essay are Parkinson’s Alley by Joy Horowitz and The Environmental Issue from Hell: Global Warming Is the Great Moral Crisis of Our Time by Bill Mckibben. Parkinson’s Alley is about residents in California’s Central Valley town of Visalia who have been diagnosed with Parkinson’s. This part of California has the highest number of people diagnosed with the neurodegenerative disease. The pesticides that are used in the surrounding farms seeps into the water that the residents use every day, causing them to get the disease. The Environmental Issue from Hell: Global Warming Is the Great Moral Crisis of Our Time is about how global warming is a moral crisis that, if not combated

Bionic Body (“Bionic”), a SEC registrant, is a biological medical device company that focuses on the development of implantable biological devices, surgical

Technical risk, a large portion of all development costs are spent on drugs that never reach the market.

There are several rewards to consider with expansion of Biocon. Currently in India, there is a growing market for contract research organization and the growth of Biocon falls right within this opportunity. The growth is expected to last for more than few years with a rate that looks promising. Clinigene is expected to reap revenues much higher than the current Biocon and Syngene combined (Kalegaonkar A., Nov 4, 2008). It will take clinical studies to a higher level with better options in terms of drug manufacturing. With other countries ready to outsource the service of clinical studies, Clinigene’s future looks bright.

EXECUTIVE SUMMARYSilicon Valley Medical Technologies (SIVMED) was founded as a research and development firm. In the beginning, SIVMED performed its own basic research, obtained patents on promising technologies, and then either sold or licensed the technologies to other firms which marketed the products. The firm has since then grown and is now contracted to perform research and testing for larger genetic engineering firms, biotechnology firms, the US government, and is now widely recognized as the leader in an emerging growth industry. SIVMED's founders were relatively wealthy individuals when they started company, and they committed a great deal of their own funds to the venture. Their personal funds, however, were soon exhausted by the

I think Medical-Surgical User team need to recommend to Dunlop the three product recommendation and in these three recommendations the first two recommendations are simple to extend the 3M product lines. But in the fourth recommendation as product development team stuck on upstream containment of infection and suppose to include upstream containment in business strategy and even if 3M Medical division enter in this infection field and applied successfully then it has become a major achievement. On the other hand if the business strategies not succeed then it shows the process of planning is unfortunate and risky for financial prospective and spend lot of time on research and